VCH-286

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H50F2N4O3
Molecular Weight	600.7826
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)N1C(=O)N(CC2CCOCC2)C[C@@]13C[C@@H]4CC[C@H](C3)N4CC[C@H](NC(=O)C5CCC(F)(F)CC5)C6=CC=CC=C6

InChI

InChIKey=YZGXEGUSPLSQOJ-MJOCGKAJSA-N

InChI=1S/C34H50F2N4O3/c1-24(2)40-32(42)38(22-25-13-18-43-19-14-25)23-33(40)20-28-8-9-29(21-33)39(28)17-12-30(26-6-4-3-5-7-26)37-31(41)27-10-15-34(35,36)16-11-27/h3-7,24-25,27-30H,8-23H2,1-2H3,(H,37,41)/t28-,29+,30-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C34H50F2N4O3
Molecular Weight	600.7826
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:36:05 GMT 2023` Edited by `admin` on `Sat Dec 16 11:36:05 GMT 2023`
Record UNII	NDX9EX5ATP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VCH-286

Code

English

CYCLOHEXANECARBOXAMIDE, 4,4-DIFLUORO-N-((1S)-3-(3'-(1-METHYLETHYL)-2'-OXO-1'-((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)SPIRO((3-EXO)-8-AZABICYCLO(3.2.1)OCTANE-3,4'-IMIDAZOLIDIN)-8-YL)-1-PHENYLPROPYL)-

Systematic Name

English

VCH286

Code

English

4,4-DIFLUORO-N-((1S)-3-((1S,5R)-3'-ISOPROPYL-2'-OXO-1'-(TETRAHYDROPYRAN-4-YLMETHYL)SPIRO(8-AZABICYCLO(3.2.1)OCTANE-3,4'-IMIDAZOLIDINE)-8-YL)-1-PHENYL-PROPYL)CYCLOHEXANECARBOXAMIDE

Systematic Name

English

Code System Code Type Description

FDA UNII

NDX9EX5ATP

Created by admin on Sat Dec 16 11:36:05 GMT 2023 , Edited by admin on Sat Dec 16 11:36:05 GMT 2023

PRIMARY

CAS

891824-47-8

Created by admin on Sat Dec 16 11:36:05 GMT 2023 , Edited by admin on Sat Dec 16 11:36:05 GMT 2023

PRIMARY

Related Record Type Details


					NDX9EX5ATP

VCH-286

ACTIVE MOIETY

Comments:

VCH-286 is being developed as a novel drug for the treatment of human immunodeficiency virus (HIV). VCH-286 (IC90 HIV-1Ba-L ~0.21 nM) targets the chemokine coreceptor CCR5 on the cell surface and specifically blocks the entry of CCR5-tropic strains of HIV-1 into host cells.


					NDX9EX5ATP

VCH-286

ACTIVE MOIETY

Comments:

IC50s obtained for VCH-286 against the R5 viruses: HIV-1BAL = 0.23 nM and HIV-1CC1/85 = 0.34 nM.


					NDX9EX5ATP

VCH-286

ACTIVE MOIETY

Comments:

Class: Antiretroviral, Small molecule; Mechanism of Action: CCR5 receptor antagonist; Highest Development Phase: Phase I for HIV infections; Most Recent Events: 12 Mar 2009 ViroChem Pharma has been acquired and merged into Vertex Pharmaceuticals, 12 Mar 2009 ViroChem Pharma has been acquired by Vertex Pharmaceuticals, 12 Feb 2009 Pharmacokinetics, adverse events and antimicrobial activity data from a phase I trial in HIV infections added